428 related articles for article (PubMed ID: 37764755)
1. New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk.
Yang K; Song M
Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764755
[TBL] [Abstract][Full Text] [Related]
2. The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus.
Bhardwaj M; Mazumder PM
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; ():. PubMed ID: 38861011
[TBL] [Abstract][Full Text] [Related]
3. Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease.
Dongoran RA; Tu FC; Liu CH
Tzu Chi Med J; 2023; 35(4):290-299. PubMed ID: 38035056
[TBL] [Abstract][Full Text] [Related]
4. Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD).
Guo Q; Li Y; Dai X; Wang B; Zhang J; Cao H
Nutrients; 2023 Aug; 15(17):. PubMed ID: 37686754
[TBL] [Abstract][Full Text] [Related]
5. The Gut Microbiome and Ferroptosis in MAFLD.
Ji J; Wu L; Wei J; Wu J; Guo C
J Clin Transl Hepatol; 2023 Feb; 11(1):174-187. PubMed ID: 36406312
[TBL] [Abstract][Full Text] [Related]
6. Hepatic Mitochondria-Gut Microbiota Interactions in Metabolism-Associated Fatty Liver Disease.
Bellanti F; Lo Buglio A; Vendemiale G
Metabolites; 2023 Feb; 13(3):. PubMed ID: 36984762
[TBL] [Abstract][Full Text] [Related]
7. The microbial metabolome in metabolic-associated fatty liver disease.
Li M; Rajani C; Zheng X; Jia W
J Gastroenterol Hepatol; 2022 Jan; 37(1):15-23. PubMed ID: 34850445
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease.
Khanmohammadi S; Kuchay MS
Pharmacol Res; 2022 Nov; 185():106507. PubMed ID: 36252773
[TBL] [Abstract][Full Text] [Related]
9. Mining Gut Microbiota From Bariatric Surgery for MAFLD.
Wu WK; Chen YH; Lee PC; Yang PJ; Chang CC; Liu KL; Hsu CC; Huang CC; Chuang HL; Sheen LY; Liu CJ; Wu MS
Front Endocrinol (Lausanne); 2021; 12():612946. PubMed ID: 33897617
[TBL] [Abstract][Full Text] [Related]
10. Oroxin B improves metabolic-associated fatty liver disease by alleviating gut microbiota dysbiosis in a high-fat diet-induced rat model.
Huang Y; Wang C; Wang M; Xiong T; Song X; Sun W; Li J
Eur J Pharmacol; 2023 Jul; 951():175788. PubMed ID: 37179040
[TBL] [Abstract][Full Text] [Related]
11. Microbial Dysbiosis Linked to Metabolic Dysfunction-Associated Fatty Liver Disease in Asians:
Yuan H; Wu X; Wang X; Zhou JY; Park S
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396863
[TBL] [Abstract][Full Text] [Related]
12. Vitamin C and vitamin D
Chen Q; Zhao L; Mei L; Zhao X; Han P; Liu J; Meng C; Li R; Zhong R; Wang K; Li J
Front Pharmacol; 2023; 14():1163694. PubMed ID: 37089915
[No Abstract] [Full Text] [Related]
13. Mapping the human oral and gut fungal microbiota in patients with metabolic dysfunction-associated fatty liver disease.
Niu C; Tu Y; Jin Q; Chen Z; Yuan K; Wang M; Zhang P; Luo J; Li H; Yang Y; Liu X; Mao M; Dong T; Tan W; Hu X; Pan Y; Hou L; Ma R; Huang Z
Front Cell Infect Microbiol; 2023; 13():1157368. PubMed ID: 37180439
[TBL] [Abstract][Full Text] [Related]
14. Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks.
Barber TM; Kabisch S; Pfeiffer AFH; Weickert MO
Metabolites; 2023 Jun; 13(6):. PubMed ID: 37367914
[TBL] [Abstract][Full Text] [Related]
15. Underlying Mechanisms behind the Brain-Gut-Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.
De Cól JP; de Lima EP; Pompeu FM; Cressoni Araújo A; de Alvares Goulart R; Bechara MD; Laurindo LF; Méndez-Sánchez N; Barbalho SM
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612504
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.
Gutiérrez-Cuevas J; Santos A; Armendariz-Borunda J
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769060
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota in MAFLD: therapeutic and diagnostic implications.
Alghamdi W; Mosli M; Alqahtani SA
Ther Adv Endocrinol Metab; 2024; 15():20420188241242937. PubMed ID: 38628492
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.
Cornejo-Pareja I; Amiar MR; Ocaña-Wilhelmi L; Soler-Humanes R; Arranz-Salas I; Garrido-Sánchez L; Gutiérrez-Repiso C; Tinahones FJ
J Gastroenterol; 2024 Apr; 59(4):329-341. PubMed ID: 38265508
[TBL] [Abstract][Full Text] [Related]
19. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome.
Abenavoli L; Scarlata GGM; Scarpellini E; Boccuto L; Spagnuolo R; Tilocca B; Roncada P; Luzza F
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984595
[TBL] [Abstract][Full Text] [Related]
20. Influence of Gut Microbiota and its Metabolites on Progression of Metabolic Associated Fatty Liver Disease.
Wang YY; Lin HL; Wang KL; Que GX; Cao T; Zhu LM; Yang X; Yang XF
Chin Med Sci J; 2023 Dec; 38(4):286-296. PubMed ID: 38097345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
